Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-11417 in myeloid malignancies
2023-508881-14-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of sonrotoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (4 arms), sponsored by BeOne Medicines. Primary endpoints: Safety and tolerability, CR + CRh rate and 2 more. Planned start Mar 2022; status: authorised.
02
Drugs
sonrotoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on 2023-508881-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508881-14-00.